BDTX-1535 is a fourth-generation, brain-penetrant EGFR inhibitor developed by Black Diamond Therapeutics, under clinical investigation for EGFR-mutant non-small cell lung cancer, including CNS metastases.
As a dedicated supplier of pharmaceutical intermediates and APIs, EOS Med CDMO offers Daraxonrasib for research and development use, We support scale-up production up to kilogram levels and provide full Drug Master File (DMF) documentation support. Every shipment comes with complete technical dossiers, including COA, MSDS, and analytical data (HPLC/HNMR), to ensure seamless regulatory compliance for your project.
Supply Capability
stock: In stock ·
Batch: up to 500 kg
Purity: 98%+ (HPLC) · GMP-compliant facility
Documentation (on request): COA / HNMR / MSDS / DMF
Specifications
CAS: 2607829-38-7
Synonyms: BDTX1535
Target: EGFR (4th-gen, brain-penetrant)
Research Area: EGFR-mutant NSCLC / CNS metastases
Transportation Conditions: This product is a non-hazardous chemical and should be transported at room temperature. It can be stably stored for several weeks during normal transportation and customs clearance.
Storage Conditions: Short-term (days to weeks) storage at 0-4°C; long-term (months to years) storage at -20°C.
Solubility: To be determined.
Shelf Life: Over 2 years under proper storage conditions.
Pharmaceutical Preparations: To be determined.
Catalyst Storage: Short-term (days to weeks) storage at 0-4°C; long-term (months) storage at -20°C.
HS Code: 2934.99.9001